The 11th Annual
Pre-Filled Syringes East Coast Conference will return to Boston in April 2024 to bring you the latest advances in the combination product drug delivery space. As part of our leading Injectable Drug Delivery Series. The 2024 conference will be bigger and better than ever, bringing you 3 days of expertise, comprising of a pre-conference focus day exploring the advances in
PFS design for enhanced drug delivery proceeded by a two-day main conference with morning keynote plenaries and parallel afternoon topic streams addressing the industry's hottest topics through case studies and industry insights.
This event will not only bring you key insights needed to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in April 2024!
Why attend:
- 3 full days of networking opportunities
- 40+ presentations with 75% of speakers from the top 20 big pharma companies
- The agenda has been curated by an advisory board of big pharma and biotech opinion leaders providing expertise focused on device development, regulatory affairs and quality
- Access a focus day and 4 dedicated streams addressing the hottest topics in the industry
What you will gain:
- Collaborate with pharma, biotech and device developers across 3 full days on the latest trends, advancements and challenges within the pre-filled syringe and injectable device market
- Hear about new technological advances for challenging to delivery drugs such as large volume, highly viscous and lyophilised formulations with case studies on wearable injectors and more
- Understand the latest regulatory requirements from experts surrounding combination products and engage in opportunities for collaboration and needs for advancing innovation in the field with an advisory board fireside chat
- Gain insight into how big pharma is incorporating sustainable approaches into drug device design and lifecycle management
- Delve into the growing potential of digital health to improve patient experience and treatment, and the challenges facing its implementation
- Examine how container and packaging development can support the ever-evolving innovations drug development, including case studies on CCIT in deep-cold storage and formulator perspectives
Who should attend
Directors, Heads of Departments and Managers for the following areas:
- Device Development
- Device Engineering
- Combination Product Development
- Drug Delivery Devices
- Primary Packaging Development
- Digital Health
- Sustainability and Circular Economy
- Large Volume Drug Delivery
- Novel Drug Product Formulation
- Regulatory Affairs
Featured Speakers
- Alex Baker, Senior Engineer II, Product and Technology Development, Biogen
- Alexandra Benbadis, Usability Leader, Sanofi
- Alicia Douglas, Human Factors Lead, Merck
- Anthony Coston, Principal Engineer, Biogen
- Bernard Vrijens, CEO & Scientific Lead, AARDEX Group
- Carrie O'Donel, Principal Device Engineer, Teva Pharmaceuticals
- Cedric Gysel, Manager, Sustainable Innovation & Circular Economy Solutions at the Office of Sustainability, Johnson & Johnson
- Charlie Dean, Head of Sustainable Medical Technology, Cambridge Consultants Ltd
- Courtney Evans, Principal Consultant, Suttons Creek, Inc.
- Danny Oseid, Product Expert - Biocompatibility, TUV-SUD
- Dany Doucet, Director Early Engagement and Deviceability, GSK
- David Morra, Director, Devices and Digital Health, Merck, Sharpe, & Dohme
- Divya Sharma, Senior Scientist, Pfizer Inc.
- Duncan Paterson, Senior Director, AstraZeneca
- E Guan, Head of Injection Systems, Takeda
- Erik Smeels, Senior Manager Packaging Engineering, Amgen
- Gang Peng, Biomedical Engineer, FDA
- Jamie Tsung, Director CMC Development, Alnylam
- John Schalago, Executive Director of Regulatory Affairs, Novartis
- Kristina Li, Sr. Engineer II, Technical Development, Biogen
- Lawton Laurence, Head of Device & Combination Product Development, Apellis
- Leya Bergquist, Associate Director, UserWise
- Madeline Mannion, Associate Director, Systems Engineering, Amgen
- Manuel Sanchez-Felix, VP Drug Delivery Search & Evaluation, Halozyme
- Mark DeStefano, Director, Combination Products and Device R&D, Teva Pharmaceuticals
- Mark Hassett, Vice President of Business Development, Credence MedSystems
- Mark Howansky, Vice President of Device Development and Commercialization, Viridian Therapeutics
- Matthew Hancock, Principal, Veryst Engineering, LLC
- Michael Song, Director, Moderna
- Mike Wallenstein, Novartis Global Head RA Medical Devices, Combination Products & Precision Medicine, Novartis Pharma AG
- Ning Yu, Executive Director, Device and Combination Product Development, Astria Therapeutics
- Peter Petrochenko, Associate Director, Regulatory Strategy, Regeneron Pharmaceuticals
- PJ Kim, VP Business Development, ApiJect Systems, Corp.
- Ravi Kaushik, Vice President, Patient Integrated Care Innovation Platform, Takeda Pharmaceuticals
- Ronald Forster, Head of Manufacturing Sciences and Technologies for Combination Product Operations, Amgen
- Sarah Fairfield, Associate Director, RA Device and Combination Products Digital Device and Software, AbbVie
- Sean Teller, Principal, Veryst Engineering, LLC
- Serene Jabary, Scientist I, Biogen
- Shai Assia, Head of Medical Devices Development, Clexio Biosciences
- Sonia Dragulin-Otto, Senior Scientist, AstraZeneca
- Soroosh Bagheriasl, Senior Account Manager, BioPhorum
- Soumen Das, Medical Device Qualification Lead & Associate Scientific Fellow, Takeda Pharmaceutical Company Limited
- Sriman Banerjee, Head of Packaging Development & CDE, Takeda Pharmaceuticals
- Sriram Natarjaan, Principal Engineer, Janssen Pharmaceuticals
- Theresa Scheuble, Head of Design & Innovation, Johnson & Johnson
- Tomohiro Suzuki, Associate General Manager, Mitsubishi Gas Chemical Company, Inc
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Sheraton Boston Hotel
39 Dalton Street,
Boston, MA, USA
